Correlation between immune-related adverse events and long-term outcomes in pembrolizumab-treated patients with unresectable hepatocellular carcinoma: A retrospective study

doi:10.4251/wjgo.v15.i4.689

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3605)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-5) series, Tables (1-3) series.

Item

Count

PDF

127

WORD

HTML

1553

Figures (1-5)

219

Tables (1-3)

181

Sum=2122

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

221

Download

472

Sum=693

Publishing Process of This Article

Item

Count

Browse

192

Download

598

Sum=790

Apr 15, 2023 (publication date) through Nov 26, 2024

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Oncol. Apr 15, 2023; 15(4): 689-699
Published online Apr 15, 2023. doi: 10.4251/wjgo.v15.i4.689

Full Size Figure Download Figure

Figure 2 Kaplan-Meier curves describing the overall survival of all patients (n = 190) and the time to progression of patients who achieved disease control (n = 99). A: Survival curve; B: Time to progression curve. OS: Overall survival; TTP: Time to progression.

Citation: Zhou JM, Xiong HF, Chen XP, Zhang ZW, Zhu LP, Wu B. Correlation between immune-related adverse events and long-term outcomes in pembrolizumab-treated patients with unresectable hepatocellular carcinoma: A retrospective study. World J Gastrointest Oncol 2023; 15(4): 689-699
URL: https://www.wjgnet.com/1948-5204/full/v15/i4/689.htm
DOI: https://dx.doi.org/10.4251/wjgo.v15.i4.689